Drug Profile
KRN 330
Alternative Names: KRN-330Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kirin Pharma Company
- Developer Kyowa Kirin
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Differentiation antigen inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 18 Oct 2012 Discontinued - Phase-I for Colorectal cancer in USA (Parenteral)
- 18 Oct 2012 Discontinued - Phase-I/II for Colorectal cancer (combination therapy) in USA (Parenteral)
- 10 Oct 2012 Kyoa Hakko Kirin terminates a phase I/IIa trial in Colorectal cancer in US (NCT00838578)